Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Destiny Pharma Ltd
Destiny Pharma Ltd
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Positive update on the development of new XF‐platform drug formulations
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development
Destiny Pharma secures £1.6 million grant to fight microbial resistance
The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment
Nick Rodgers joins Destiny Pharma
Research & Development
Destiny Pharma announces research collaboration with Aston University
Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media
Destiny Pharma establishes Scientific Advisory Board
Pharmaceutical
Destiny Pharma appoints Neil Clark new CEO
Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients
Destiny Pharma receives US FDA QIDP designation for novel antibacterial product
Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now